In intermediate risk AML, effect of FLT3 burden is modulated by NPM1 mutation, especially in patients with a low ratio.
Introduction
Presence of FLT3-ITD is associated with an increased risk of relapse (RR) and inferior overall survival (OS) in patients with normal karyotype AML, arising as one of the main prognostic factors in this group of patients [1] [2] [3] [4] . However, the risk conferred by this mutation has been related to specific characteristics, such as the allelic burden, length of the mutation or specific sequence 4, [5] [6] [7] . Thus, the proportion of the mutant allele among leukemic population is considered one of the most important features modulating the prognostic impact of the mutation 6, 7 .
Nonetheless, the resulting effect of the FLT3-ITD is not only a consequence of intrinsic characteristics of the mutation but can also depend on the interaction with other mutations, such as WT1 or DNMT3A, which seem to add an adverse effect in patients with FLT3-ITD AML [8] [9] [10] . Moreover, FLT3-ITD, considered as a secondary mutation involving signaling cell pathways which confer a proliferation advantage to the leukemic clone (type I mutation), is frequently observed in patients harboring NPM1 mutations, associated to a favorable prognosis [11] [12] [13] [14] . Therefore, the effect of FLT3-ITD burden might depend on the presence or absence of an underlying NPM1 mutation, as recently suggested [15] [16] [17] . To test this hypothesis we analyzed a large series of patients with a long follow-up from the Spanish cooperative group CETLAM. 
Results and discussion

Characteristics of patients
Main characteristics of patients are summarized in Supplementary Table 2. FLT3-ITD and NPM1 mutations were determined in 303 patients and were detected in 94 (31%) and 161 (53%) patients respectively, with a significant association between them (65 patients harbored both mutations, p<0.001). 
Patients with FLT3-ITD, compared to
Outcome and prognostic factors
Overall, CR rate was 85%, and OS and LFS at 5-yr were 43±3% and 46±3%.
The only factor predictive of CR achievement was a lower WBC at diagnosis (91% vs 79%; p=0.004). Univariate and multivariate prognostic studies are summarized in Table 1 and Supplementary Table 3 (Figure 1 ).
We analyzed the potential benefit of alloHSCT in CR1 according to molecular features. First, to avoid a negative bias for patients allocated in the nonalloHSCT arm, we restricted the analysis to patients with a minimum CR duration of three months. In the NPM1mut group, high ratio patients of the leukemogenic process 21 . Thus, the prognosis of these latter patients might not be determined as much by constitutional activation of FLT3 pathway as by other relevant leukemogenic mutations, like NPM1 mutation. This prognostic interaction between NPM1 mutational status and FLT3-ITD/wt ratio, confirmed in our series, has only been identified in two previous studies 15, 16 , although FLT3-ITD/wt ratio in these two studies was determined on cDNA instead of usual determination on gDNA.
Despite some controversial results, a general recommendation to perform an early alloHSCT in younger AML patients with FLT3-ITD AML has been Catalunya. MP holds a grant "Río Hortega" from ISCIII (CM08/00027).
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